In this webinar, we delve into the synthetic methodologies, pharmacology and overall drug discovery considerations associated with the development of covalent inhibitors in drug discovery. The most important points are highlighted using flagship case studies containing valuable industry insight.

Covalent inhibition has seen a rebirth in the last decade. Prosecuting covalent inhibitor programmes requires a complete rethinking of the drug discovery process. This webinar, in association with Concept Life Sciences, aims to provide the foundations and emerging paradigms in covalent drug discovery.

The content has been designed for scientists with a general interest in drug discovery. No prior knowledge is required, and this webinar also acts as a tutorial.

By watching this webinar you will:

  • Learn about the fundamental aspects of developing covalent inhibitors in drug discovery
  • Discover more about the new warheads under development
  • Understand the in-vitro and in-vivo considerations associated with this therapeutic strategy
  • Develop a feel for the emerging paradigms in this field

Tilly Bingham Concept Life Sciences

Speaker: Matilda Bingham (Tilly), VP of science, Concept Life Sciences

With over 18 years experience, Tilly’s current role oversees multiple programmes in drug discovery. An elected member of the RSC’s organic division and a member of the SCI fine chemicals group, Tilly has authored over 40 papers, patents and publications including the RSC book ’Drug Discovery for Psychiatric Disorders’.

 

Jamie Stokes Concept Life Sciences

Speaker: Jamie Stokes, principal scientist, Concept Life Sciences

Following a PhD from the University of Cambridge, Jamie was a Roche Postdoctoral Research Fellow working at the chemistry-biology interface. Jamie has since worked at Concept Life Sciences on a number of different medicinal chemistry programs and has a special interest in new approaches to synthesis and antibody drug conjugates.

 

Daniel Glynn Concept Life Sciences

Speaker: Daniel Glynn, principal scientist, Concept Life Sciences

Daniel is a principal scientist at Concept Life Sciences with 9 years of experience in medicinal and organic chemistry and has worked on projects spanning oncology, inflammation and metabolic disorders. Daniel has a keen interest in areas of epigenetics, synthetic lethality and PROTAC development and to date is the author of 4 journal publications and patents.

 

Caroline Rigby Concept Life Sciences

Speaker: Caroline Rigby, senior chemist, Concept Life Sciences

Caroline completed her DPhil at the University of Oxford and subsequently gained postdoctoral experience at the University of Manchester before taking up her current position as senior chemist. She has worked on a wide variety of projects for CLS and has a keen interest in medicinal chemistry and emerging technologies.

 

Ben Valsler

Moderator: Benjamin Valsler, digital editor, Chemistry World

Ben is the digital editor of Chemistry World magazine, producing video and podcasts to accompany the magazine and website. Prior to joining the Royal Society of Chemistry, he was the producer of the award-winning Naked Scientists, making local and national radio programmes for the BBC, the Australian Broadcasting Corporation and Primedia in South Africa.

Concept Life sciences (a Spectris company) logo

Concept Life Sciences offers a comprehensive range of discovery and development services and analytical solutions across the pharmaceutical, biotechnology, agrochemical and food sectors.

We’ve been delivering projects globally for over 25 years and our team of 250+ scientists has extensive experience in multiple therapy areas with specialist expertise in immunology, oncology and neuroscience.

We offer a comprehensive range of discovery and development services and analytical solutions across the pharmaceutical, biotechnology, agrochemical and food sectors. Our services are built on expert knowledge, collaboration, flexibility and extensive in-house resources.

Topics